This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gega, M. Articles by Yamamura, T. Search for Related Content PubMed PubMed Citation Articles by Gega, M. Articles by Yamamura, T.

Successful Chemotherapeutic Modality of Doxorubicin Plus Dacarbazine for the Treatment of Desmoid Tumors in Association With Familial Adenomatous Polyposis

From the Second Department of Surgery; Laboratory of Hereditary Tumor, Institute for Advanced Medical Sciences; Department of Genetics, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan

Address reprint requests to Reigetsu Yoshikawa, MD, PhD, Second Department of Surgery, Hyogo College of Medicine, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan; e-mail: yosikr2s{at}hyo-med.ac.jp

PURPOSE: Desmoid tumors are locally aggressive and can be fatal in familial adenomatous polyposis (FAP) patients if they are not suitable for surgery or radiation therapy. Here, we prospectively investigated the efficacy of a chemotherapeutic regimen involving doxorubicin (DOX) and dacarbazine (DTIC) for inoperable FAP-associated desmoid tumors.

PATIENTS AND METHODS: From an initial group of 120 FAP patients, seven of the 11 individuals with symptomatic unresectable desmoid tumors that were unresponsive to conventional hormone therapy were enrolled onto this study. The general chemotherapy regimen comprised four or five cycles of DOX (20 mg/m² daily) plus DTIC (150 mg/m² daily) throughout 4 days of drip intravenous infusion (day 1 through 4) every 28 days, followed by the cyclooxygenase–2 inhibitor meloxicam (10 mg/m²). The primary end point was relapse-free survival. The secondary end points included toxicity, clinical improvement, and tumor regression according to computed tomography.

RESULTS: Significant tumor regression was observed clinically and radiologically in all seven patients. Three patients showed a complete response. The average progression-free survival period was 74.0 months (range, 32.5 to 107.5 months). Three patients showed grade 3 adverse events with no treatment-related mortality. All seven patients survived and remained without tumor progression. An adenomatous polyposis coli germline–mutation analysis revealed no mutations in the specified regions.

CONCLUSION: A chemotherapeutic regimen of DOX plus DTIC followed by meloxicam is an effective and safe treatment for FAP-associated desmoid tumors. This modality should be considered for use as first-line chemotherapy in symptomatic desmoid tumors that are unresponsive to conventional medical therapy, due to the absence of useful presymptomatic markers.

Presented in part at the 41st American Society of Clinical Oncology Meeting, Orlando, FL, May 13-17, 2005.

M.G. and H.Y. contributed equally to this work.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				H F A Vasen, G Moslein, A Alonso, S Aretz, I Bernstein, L Bertario, I Blanco, S Bulow, J Burn, G Capella, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP) Gut, May 1, 2008; 57(5): 704 - 713. [Abstract] [Full Text] [PDF]

				K. Ezumi, H. Yamamoto, I. Takemasa, M. Nomura, M. Ikeda, M. Sekimoto, and M. Monden Dacarbazine-Doxorubicin Therapy Ameliorated an Extremely Aggressive Mesenteric Desmoid Tumor Associated with Familial Adenomatous Polyposis: Report of a Case Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 222 - 226. [Abstract] [Full Text] [PDF]

				S. Signoroni, M. Frattini, T. Negri, E. Pastore, E. Tamborini, P. Casieri, M. Orsenigo, L. Da Riva, P. Radice, P. Sala, et al. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis Clin. Cancer Res., September 1, 2007; 13(17): 5034 - 5040. [Abstract] [Full Text] [PDF]

				D. Lev, D. Kotilingam, C. Wei, M. T. Ballo, G. K. Zagars, P. W.T. Pisters, A. A. Lazar, S. R. Patel, R. S. Benjamin, and R. E. Pollock Optimizing Treatment of Desmoid Tumors J. Clin. Oncol., May 1, 2007; 25(13): 1785 - 1791. [Abstract] [Full Text] [PDF]

				S. X. Skapek, W. S. Ferguson, L. Granowetter, M. Devidas, A. R. Perez-Atayde, L. P. Dehner, F. A. Hoffer, R. Speights, M. C. Gebhardt, G. V. Dahl, et al. Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II Trial J. Clin. Oncol., February 10, 2007; 25(5): 501 - 506. [Abstract] [Full Text] [PDF]

				A. Goncalves, G. Monges, Y. Yang, F. Palmerini, P. Dubreuil, T. Noguchi, J. Jacquemier, D. Di Stefano, J.-R. Delpero, H. Sobol, et al. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst, April 19, 2006; 98(8): 562 - 563. [Full Text] [PDF]

				S. R. Patel and R. S. Benjamin Desmoid Tumors Respond to Chemotherapy: Defying the Dogma in Oncology J. Clin. Oncol., January 1, 2006; 24(1): 11 - 12. [Full Text] [PDF]